<?xml version="1.0" encoding="UTF-8"?>
<p>Therefore, it is necessary to assess the age-specific immunity to JE to make an appropriate vaccination policy to control JE. There have been studies on the immunogenicity of the JE vaccine for children [
 <xref rid="B12-vaccines-08-00328" ref-type="bibr">12</xref>,
 <xref rid="B13-vaccines-08-00328" ref-type="bibr">13</xref>], but there is a lack of prospective studies on JE-neutralizing antibodies (NTAbs), which were conducted on the general population in Korea. Moreover, most of the studies on the seroprevalence of JE in Korea were conducted between the 1960s and 1990s [
 <xref rid="B14-vaccines-08-00328" ref-type="bibr">14</xref>], and these studies were confined to small local areas. The aim of this study was to investigate the age-specific prevalence of JE-NTAbs among the general population above 15 years old in Korea.
</p>
